A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma

BACKGROUND: IL-13 has been implicated in the development of airway inflammation and hyperresponsiveness. This study investigated the multiple-dose pharmacokinetics and safety profile of human anti-IL-13 antibody (CAT-354) in adults with asthma. METHODS: This was a multiple-dose, randomised, double-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Dave, Kane, Binita, Molfino, Nestor A, Faggioni, Raffaella, Roskos, Lorin, Woodcock, Ashley
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820465/
https://www.ncbi.nlm.nih.gov/pubmed/20064211
http://dx.doi.org/10.1186/1471-2466-10-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820465/
https://www.ncbi.nlm.nih.gov/pubmed/20064211
http://dx.doi.org/10.1186/1471-2466-10-3

Ejemplares similares